Meeting 1: 1:00PM - 1:20PM
Meeting 2: 1:20PM - 1:40PM
Jamie Pearson
General Counsel & Chief Compliance Officer
Shionogi Europe
Ianina Liebold
Senior Director Legal
BioNTech
Marcell Komlosi
Patent Counsel
Debiopharm International SA
Meeting 1: 3:45PM - 4:00PM
Meeting 2: 4:00PM - 4:15PM
Meeting 1: 1:20PM - 1:40PM
Meeting 2: 1:40PM - 2:00PM
Meeting 1: 10:40AM - 11:00AM
Meeting 2: 11:05AM - 11:25PM
Peter Schedereit
Case Handler, DG Competition Unit E.1
European Commission
Due to be implemented across Member States by December 2026, the new EU Product Liability Directive (PLD) introduces a fundamental shift in life sciences legal risk, marked by potential reversals of the burden of proof onto defendants, expanded disclosure obligations and new limitation periods of up to 25 years. When coupled with other EU developments, including the growth of third-party litigation funding, these changes are expected to increase exposure to class actions and multiparty litigation, drive higher insurance costs and make the defence of product liability claims materially more complex for life sciences companies. This session will examine the key changes under the EU PLD and explore their implications for life sciences companies operating across Europe.
Simon Neill
Assistant General Counsel
Johnson & Johnson
Wouter Mooij
Dutch & European Patent Attorney, UPC Representative
De Vries & Metman
Wouter Mooij is Head of Chemistry & Life Sciences at De Vries & Metman. He oversees the prosecution of patent portfolios covering small molecule therapeutics, drawing on his background in medicinal chemistry and his extensive experience in patent litigation. His clients range from early‑stage spin‑outs to global pharmaceutical companies. Wouter brings a practical, strategic perspective to this panel on AI‑discovered therapeutics.